Norursodeoxycholic acid

Drug Profile

Norursodeoxycholic acid

Alternative Names: NorUDCA; Ursodeoxycholic acid homologue

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dr Falk Pharma
  • Class Cholic acids; Gallstone therapies; Hepatoprotectants
  • Mechanism of Action Cholesterol inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Primary sclerosing cholangitis

Most Recent Events

  • 29 Aug 2017 Chemical structure information added
  • 07 Aug 2017 Dr. Falk Pharma plans a phase III trial for Primary sclerosing cholangitis in Austria (EudraCT2016-003367-19)
  • 01 Aug 2017 Phase-III clinical trials in Primary sclerosing cholangitis in Austria (PO) (EudraCT2016-003367-19)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top